Elekta Versa HD system launched in Kenya for advanced cancer treatment

HCG CCK Cancer Centre, a unit of Healthcare Global Enterprises Limited leading oncology chain in India has launched Elekta’s Versa HD to offer advanced cancer treatment for patients in Kenya.

Versa HD is an advanced linear accelerator designed to treat a broad spectrum of cancers and significantly enhance patient care and is the first to be launched in sub-Saharan Africa. It provides clinicians with the dual flexibility to deliver conventional therapies to treat a wide range of tumours, as well as high-precision targeted therapies for treating highly complex cancers.

As an integrated treatment system, it helps address the evolving challenges of modern-day cancer management while providing patients with best-in-class treatment and high-quality clinical care. The technology helps minimise the radiation dose to healthy tissue and improve quality of life. Cancer patients in Nairobi can now utilize the service for better treatment outcomes.

The Elekta Versa HD will also reduce the overall patient treatment duration currently upto 5 to 7 weeks currently for standard treatments to a maximum of 1(one) week with the overall advantage of considerably reduced treatment side effects experienced among patients being treated using hypofractionated regimens. This is enabled through protection of organs at risk and normal tissue. 

“Being the pioneers in adopting advanced technologies for cancer therapies, HCG is proud to introduce Elekta’s Versa HD, yet another market-leading innovation. It has been our ceaseless endeavour to provide personalized and precise cancer treatment to our patients. HCG has been at the forefront of adopting cutting-edge technologies in the fight against cancer and the launch of the Versa HD system is a key milestone in this direction. Equipped with this latest technology, HCG CCK Cancer Centre will be better equipped to provide patient-centric, best-in-class medical services.”  Dr. BS Ajaikumar, Executive Chairman, Healthcare Global Enterprises Limited, said. 

Hon. Dr. Mercy Mwangangi, Chief Administrative Secretary, Ministry of Health, Kenya who also attended the launch commended HCG CCK Cancer Centre for being the first hospital to introduce this latest technology in the sub-Saharan region of Africa. ”Elekta’s Versa HD will help improve the quality of life of oncology patients and rationalize treatment costs of tumour diseases in the region. As a leading cancer care specialist, HCG has always been instrumental in bridging the quality and accessibility gap for patients, and with this initiative, we are sure to witness the best treatment outcomes.” she said. 

The Elekta Versa HD can treat up to 150 patients in a day. Patients who utilize the Elekta Versa HD will have an access to the best outpatient Oncology care here at HCGCCK and the region. Previously, cancer patients had to travel overseas to countries like India to receive this specialized treatment.  This treatment will now be available for them locally. 

“We are excited to collaborate with HCG Cancer hospital, which is committed to enhancing the accessibility of quality cancer care. Elekta is using precision radiation therapy to work towards a future where everyone can benefit from precise and individually tailored radiotherapy treatments. With Versa HD, clinicians can deliver cutting-edge radiation therapy and offer people dealing with cancer a prolonged, disease-free life. Like HCG, our goal is to ensure every patient has access to the best cancer care possible.” Mr. Habib Nehme, Executive Vice President, Elekta, said.

Follow us on TelegramTwitterFacebook, or subscribe to our weekly newsletter to ensure you don’t miss out on any future updates. Send tips to

Facebook Comments

Samsung’s Galaxy Z Fold6 and Z Flip6 Kenya Launch

Nixon Kanali

Tech journalist based in Nairobi. I track and report on tech and African startups. Founder and Editor of TechTrends Media. Nixon is also the East African tech editor for Africa Business Communities. Send tips to

Have anything to add to this article? Leave us a comment below

Back to top button